CD4 and pneumocystosis: The incidence rate of pneumocystosis following discontinuation of primary and secondary prophylaxis among HIV-infected patients when their CD4 counts increased to ≧200 cells/μL after receiving HAART in published studies ranges from 0 to 2.27 cases per 100 PY of follow-up, depending on the types of study design and observation duration [3,11,15-25].